Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Glaxo Wellcome
In this open-label study antiretroviral-naive patients are randomized to one of two drug regimens:
Arm I: 141W94 (amprenavir), 1592U89 (abacavir), and Combivir (3TC/AZT tablet). Arm II: Nelfinavir and Combivir.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
CD4 count \> 50.
HIV RNA \> 5,000.
No active AIDS (excluding CD4 count \< 200).
Ability to comply with dosing schedule and protocol evaluations.
Prior Medication:
Allowed:
3TC or any protease inhibitor, if \< 1 week of therapy.
Other nucleoside analogs, if \< 4 weeks of therapy.
You may not be if
Co-existing Condition:
Patients with any of the following symptoms or conditions are excluded:
Active AIDS (not including CD4 count \< 200).
Malabsorption syndrome affecting drug absorption.
Concurrent Medication:
Excluded:
Enrollment in any other investigational drug protocol.
Prior Medication:
Excluded:
Non-nucleoside reverse transcriptase inhibitors.
Clareo Health | A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment
